NPCE Earnings Prediction
The chart below shows how NPCE performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NPCE sees a +6.82% change in stock price 10 days leading up to the earnings, and a -10.88% change 10 days following the report. On the earnings day itself, the stock moves by +0.97%. This data can give you a slight idea of what to expect for the next quarter's release.
NPCE Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
21.06M
28.20%
9.37%
Gross Margin
73.22%
-1.68%
-0.25%
Operating Margin
-20.15%
-44.37%
-37.71%
Net Margin
-25.89%
-41.40%
-33.65%
EPS
-0.19
-32.14%
-26.92%
No Data Available
NPCE Earnings Analysis
Neuropace, Inc. Common Stock Corporation (NPCE.O) Earnings Conference Call
Positive
Q3 Revenue Increase: Total revenue for Q3 2024 was $21.1 million, representing a 28% increase compared to $16.4 million for the same period last year.
RNS Sales Surge: RNS sales grew by 36% in Q3 2024, contributing significantly to the overall revenue growth.
Gross Margin Consistency: Gross margin for Q3 2024 was 73.2%, consistent with the target range of 72% to 74%.
R&D Expense Increase: R&D expense increased to $5.8 million in Q3 2024, up from $4.8 million in the same period of 2023, reflecting investment in product development.
Cash Balance Increase: Cash balance increased from $55.5 million at the end of Q2 2024 to $56.8 million at the end of Q3 2024, supporting future operations.
Negative
Q3 Revenue and Loss Analysis: Revenue for Q3 2024 was $21.1 million, representing a net loss of $5.5 million compared to a loss of $7.3 million in Q3 2023.
R&D Expense Increase: R&D expense increased to $5.8 million in Q3 2024 from $4.8 million in the same period of 2023, driven by increased personnel and program expenses.
SG&A Expense Increase: SG&A expense was $13.9 million in Q3 2024 compared to $13.4 million in the prior year period, primarily due to increased sales and marketing personnel expenses.
Operating Expenses Increase: Total operating expenses were $19.7 million in Q3 2024 compared to $18.2 million in the same period of the prior year, representing an 8% increase despite revenue growing by 28%.
Operational Loss Comparison: Loss from operations was $4.2 million in Q3 2024 compared to $6 million in the prior year period, indicating ongoing operational challenges.
NPCE FAQs
How does NPCE typically perform around its earnings report dates?
Is NeuroPace, Inc. (NPCE) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
NPCE Earning Call Sentiment
NeuroPace, Inc. (NPCE) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
NPCE.O
7.7%Positive
The earnings call shows positive revenue growth and reduced losses, but is tempered by high operating expenses and debt. The Q&A reveals optimism in growth initiatives like Project CARE and sales expansion, but management's vague responses on hiring and future revenue curves raise uncertainties. The slight revenue guidance increase and stable gross margins are positive, but the financial risks from debt and potential headwinds balance this out. Overall, the sentiment is neutral as the positives are offset by financial and strategic uncertainties.